Scientific Data of Functional Food
Reports of Recovery from Disease due to BRM4 - Cases 12-29
Please note that these reports make reference to MGN-3. BRM4 was previously sold under the name of
MGN-3 in the USA.
| No.12 Bladder Carcinoma |
| NAME/F.S. |
AGE/47 |
SEX/Female |
RESIDENCE/U. S. A. |
| Clinical Record and Treatment |
|
The patient was diagnosed with stage 1 bladder carcinoma at Drew University Hospital, CA on
October 14, 1994. The patient immediately started chemotherapy and continued it for 6 months. On February 14,
1995, an edema was found in the patient's leg. The patient started receiving 3 g MGN-3 per day (1g/dose). The
patient was able to return to her usual daily activities and to teach classes all day long, which is her
occupation. The patient's CT scan was normal and there were no symptoms of recurrence during an examination
on February 15, 1997.
Evaluation
The patient's bladder carcinoma disappeared due to chemotherapy and MGN-3, and recurrence
has been prevented. At present, the patient's NK cell activity is being maintained at a high level and the
androgenic hormone levels are normal, so it appears that there is no risk of recurrence.
|
|
| No.13 Chronic Hepatitis, Type B, and Liver Cancer |
| NAME/Y.K. |
AGE/44 |
SEX/Male |
RESIDENCE/Fukuoka Prefecture |
| Clinical Record and Treatment |
The patient has a history of viral hepatitis, type B, and was diagnosed with active
chronic hepatitis (HbeAg+, HbeAb-) in June 1996 at K hospital in Fukuoka Prefecture. The patient's GOT
and GPT levels were 85 and 93 respectively. The patient immediately entered the hospital and the
condition slowed temporarily with some rest and treatment with Major Minofargen C. The patient left the
hospital in April 1994. The GOT and GPT levels fluctuated between 50 and 70 and between 55 and 80
respectively. In November 1997, the patient visited O clinic complaining of fever and severe fatigue. The
tumor marker CA 19-9 increased to 78 and two tumors was found in the patient's liver upon close
examination. The patient started taking 3 g of MGN-3 daily (1g per dose) in January 1998. The severe
fatigue was reduced with the administration of MGN-3 and the level of CA19-9 decreased to 66 three months
later (April 1998). Moreover, HbsAg decreased gradually and was eventually not detected. HbeAb, on the
other hand, increased. HbsAg was 47.9 at the beginning of the administration of MGN-3, but the level
decreased to 36.9 three months later. At present, the patient's transaminase activity is stable, which
means that GOT and GPT are 41 and 37 respectively.
Fig. Change in transaminase activity
Changes due to MGN-3
The patient's fatigue was initially lessened by MGN-3 administration and appetite
increased. Pain in the liver was dulled.
Evaluation
This is a case of type-B Chronic Hepatitis with advanced liver cancer; the tumor marker
started declining with MGN-3 administration and declined steadily for 3 months. One of the tumors
disappeared 4 months later. Moreover, hepatitis B e antigen disappeared and hepatitis B e antibody
increased. Hepatitis B surface antigen is decreasing. This implies improvement of the patient's immune
system, and MGN-3 administration is expected to relieve the Chronic Hepatitis and prevent the recurrence
of liver cancer.
|
|
| No.14 Chronic Hepatitis, Type B, and Liver Cancer |
| NAMES.G. |
AGE/56 |
SEX/Male |
RESIDENCE/Fukuoka Prefecture |
| Clinical Record and Treatment |
The patient had been diagnosed with active viral type-B hepatitis with hepatitis B e
antigen+ and hepatitis B e antibody- since the age of 45. Suffering from extensive headaches and
nausea, the patient visited O clinic on October 11, 1996. Concerning the patient's transaminase
activity, GOT, GPT, hepatitis B e antigens, and AFP were 85, 74, 55.5, and 210, respectively. The
diagnosis of hepatitis type-B advanced liver cancer was doubted, and close examination revealed two
tumors in the patient's liver. The patient started to receive 3 g MGN-3 daily (1g/dose). The patient
was relieved of nausea after 3 days. An examination two months later on December 20th indicated that
GOT, GPT, Hepatitis B surface antigens, and AFP were 220, 160, 49.2, and 180, respectively. The
patient's health had improved and fatigue had lessened. Results of an examination on February 27,
1997 demonstrated that GOT, GPT, hepatitis B surface antigens, and AFP(αfetoprotein) were 42, 46,
35.9, and 18.
Fig. Change in transaminase activity 
Changes due to MGN-3
Three days after starting MGN-3 administration, the patient's nausea was alleviated
and body temperature decreased from 38℃ to 37℃. Afterwards, the patient recovered his appetite and
strength.
Evaluation
This is a typical case of type-B chronic hepatitis with advanced liver cancer, so
some improvement was detected due to taking 3 g MGN-3 per day. The transaminase activity rose
temporarily after the start of MGN-3 administration, and it then rapidly declined and reached normal
levels three months later. Hepatitis B surface antigen, which measures the degree of infection for
type-B hepatitis, has declined gradually, and that implies that the patient's viral-B hepatitis load
also has been decreasing gradually. Since this improvement has been seen in such a short period,
MGN-3's level of immunopotentiation activity is considered to be relatively high. Henceforth, MGN-3
may relieve the patient of type-B hepatitis and prevent the recurrence of liver cancer.
|
|
| No.15 Chronic Hepatitis, Type C |
| NAME/Y.Y. |
AGE/65 |
SEX/Male |
Period of MGN-3 Administration/Jan. 8~Mar. 10, 1998 |
| NAME/S.K. |
AGE/63 |
SEX/Female |
Period of MGN-3 Administration/Aug. 8~Nov. 20, 1998 |
| NAME/M.A. |
AGE/75 |
SEX/Female |
Period of MGN-3 Administration/Oct. 17, 1998~Jan, 20,
1999 |
| NAME/N.S. |
AGE/64 |
SEX/Male |
Period of MGN-3 Administration/Sep. 15~Dec. 20, 1998 |
| Clinical Record and Treatment |
3 g MGN-3 per day was administered for three months to four (4) patients
consisting of 2 males and 2 females who suffered from type-C chronic hepatitis in order to
confirm MGN-3's effect on the disease. All of the patients' conditions of type-C hepatitis
improved immensely during the three months.
Fig. Results of examination
Changes due to MGN-3
Three days after starting MGN-3 administration, the patient's nausea was
alleviated and body temperature decreased from 38℃ to 37℃. Afterwards, the patient recovered his
appetite and strength.
Evaluation
Patient Y.Y.'s transaminase activity kept gradually increasing until 30 days
after the initial administration of MGN-3. Subsequently it continued to decline, and the GOT and
GPT levels reached 46 and 42 respectively 90 days later. HCV antibody decreased from 7.8 to
5.3.
Patient S.K.'s transaminase activity increased when the patient started taking
MGN-3 to more than 2.5 times its level 20 days prior. Subsequently, activity kept decreasing and
the GOT and GPT levels reached 43 and 43, respectively.
Patient M.A. did not experience a significant results in terms of transaminase
activity, but HCV antibody declined from 7.4 to 5.5.
Patient N.S.'s transaminase activity was high at the beginning of MGN-3
administration. Subjective symptoms included severe fatigue and loss of appetite along with a
fever. Transaminase activity declined substantially after the patient started taking MGN-3, and
the levels of GOT and GPT eventually reached 18 and 14, respectively. HCV antibody decreased from
5.5 to 3.3.
The aforementioned results seem due to the immunopotentiation, which not only
reduced the hepatitis symptoms but also eliminated the viruses by promoting NK cell activity and
the production of Interferon Gamma. Continuation of MGN-3 administration will lead to the
alleviation of hepatitis symptoms and reduce the risk of cirrhosis.
|
|
| No.16 Primary Malignant Lymphoma of the Left Breast |
| NAME/O.T. |
AGE/75 |
SEX/Female |
RESIDENCE/Osaka Prefecture |
| Clinical Record and Treatment |
| In November 1998, the patient had her left breast removed due to
breast cancer. The patient then received hormone therapy in six cycles and finished the
therapy at the end of April 1998. The patient had a local recurrence as was found during an
ambulatory medical examination in June 1998. In addition, tumor marker CA 15-3 was 85U. The
patient received chemotherapy presupposing ambulatory medical treatment. Chemotherapy
medication consisted of: |
| 1st week |
Melphalan |
4mg 4 days |
| 2nd week |
Methotrexate |
2.5mg 3 days |
| 3rd week |
Procailazine |
100mg 3 days |
| 4th week |
Cyclophosphamide |
50mg every day |
In addition to these chemotherapeutics, the patient took 3 g MGN-3 per day.
Significant results had been detected since the first cycle in that the tumor grew smaller
and the level of CA15-3 declined to 45. After the second cycle, ambulatory treatment appeared
possible, and the patient left the hospital on July 20th. Then, the patient received 4 cycles
of chemotherapy in total. The tumor marker consistently decreased and CA15-3 was within
normal ranges. 
A point deserving special attention is the fact that the patient continued ambulatory
treatment with slight adverse effects even though she was 75 years of age. This appears to be
due to the effects of MGN-3. Furthermore, the fact that chemotherapeutics had significant
efficacy may also imply that there was a synergistic effect between MGN-3 and
chemotherapeutics.
Changes due to MGN-3
It is worth noting that the patient did not have a loss of appetite and
experienced little loss of energy during the administration of chemotherapeutics.
Evaluation
Chemotherapy was used to prevent the recurrence of breast cancer. In
addition to chemotherapy, the patient took MGN-3 to prevent impairment of the immune system
and to enhance the effectiveness of chemotherapeutics. The result was truly satisfactory. The
chemotherapy was effective and the four cycles of treatment led to remission. A fundamental
study has reported that MGN-3 administration of 5 FU in effective in preventing the reduction
of NK cell activity, so the reduction of adverse effects for this patient was as expected.
Obviously, the adverse effects were prevented and the patient thus maintained physical
strength during the treatment.
|
|
| No.17 Articular Rheumatism |
| NAME/S.O. |
AGE/74 |
SEX/Female |
RESIDENCE/Kobe Prefecture |
| Clinical Record and Treatment |
The patient visited I clinic on April, 1998 complaining of arithralgia of
the limbs. The pain in the knees and ankles was especially severe, and the patient had
dysbasia. The patient was diagnosed with arthritis mutilans after a blood test and
X-rays. In addition to conventional treatment, the patient received 1 g/day MGN-3 for a
week, and the dose was then increased to 3g/day. The pain in the knees and ankles
weakened around 2 weeks after taking MGN-3, and the patient did not have difficulty
walking 1 month later. Stiffness in the fingers improved 6 month later and the patient
did not particularly experience limitations in terms of usual activities. As of January
1999, the rheumatism index is ± and the symptoms are stable, indicating CRP(cyclic AMP
receptor protein) is 0.6 and within normal ranges. 
Changes due to MGN-3
One week after starting MGN-3 administration, the patient became to
sleep soundly and felt diminishing pain in the limbs. Since the dysbasia was alleviate in
the early stage, the patient was very pleased.
Evaluation
Inflammation inhibition has been reported as one of the effects of
MGN-3. While patients with articular rheumatism usually have a low level of NK cell
activity, MGN-3 was prescribed in this case of arthritis mutilans in order to increase NK
cell activity. The fact that MGN-3's effectiveness became apparent in a short period of
time was significant subjectively and serologically. The RA test improved from ++ to ± 9
months later, and CRP declined from 2.0 to normal ranges. This case is noteworthy in that
the physiological activity of MGN-3 was clinically reflected.
|
|
| No.18 Lung Cancer/Lib Metastasis |
| NAME/S.K. |
AGE/67 |
SEX/Male |
RESIDENCE/Osaka Prefecture |
| Clinical Record and Treatment |
In August 1996, the patient visited the Departments of Respiratory
Medicine and Surgery at H hospital because he lost weight rapidly and suffered from a
hacking cough with sputum. Results of examination served to diagnose the patient with
complications relating to lung cancer and pulmonary tuberculosis. After the treatment
of pulmonary tuberculosis with antibiotics, which took preference, the patient
started treatment for lung cancer in the form of irradiation therapy along with
treatment of pulmonary tuberculosis in October. That December, prospective treatment
for pulmonary tuberculosis became possible and a tumor was removed by resection of
1/2 of the lower part of the right lung. After irradiation therapy, the patient left
the hospital in January 1997. After 5 months, the patient had pain in his right
thoracic region and multiple bone metastasis was found upon examination. Tumors were
spread throughout the patient's body with a primary site in the ribs of the right
thoracic region. 3 g MGN-3 per day was administered with an analgesic, morphine. Six
months after starting MGN-3 administration, the pain lessened and the quantity of
morphine was reduced gradually. In June 1998, the patient did not feel pain although
he stopped taking morphine. The tumor marker was 16.8 in June 1997 at the beginning
of MGN-3 administration and declined to 7.6 in December 1997 and 6.7 in June 1998,
respectively. Significant improvement was observed with a bone scintigram, and
metastasis to bone had obviously lessened. 
Changes due to MGN-3
The patient felt the type of pain in his right thoracic region
change 1 month later after taking MGN-3, and the pain had obviously lessened 6 months
later.
Evaluation
There is no effective way with today's medicine to cure multiple
bone metastasis where tumors spread throughout the body. Metastasis that had
developed rapidly gradually slowed and shrunk due to the immunopotentiation of MGN-3.
As of June 1998, the tumor marker is not within normal ranges, but a continuous
intake of MGN-3 should lead to further improvement and remission of the disease. In
addition, similar treatment was used in an extremely similar case involving a
77-year-old female, and treatment has followed a similar process, reducing bone
metastasis and pain.
|
|
| No.19 Breast Cancer |
| NAME/K.T. |
AGE/39 |
SEX/Female |
Period of MGN-3
Administration/February 24, 1997 ~ December 3,
1998 |
| NAME/M.D. |
AGE/74 |
SEX/Female |
Period of MGN-3
Administration/August 2, 1997 ~ February 10,
1999 |
| NAME/M.T. |
AGE/54 |
SEX/Female |
Period of MGN-3
Administration/September 2, 1998 ~ February 10,
1999 |
| Clinical Record and Treatment |
|
3 patients with breast cancer took 3g of MGN-3 per day
continuously in order to confirm the effectiveness of MGN-3.
Patient K.T. had surgery on her right breast due to breast
cancer. One and a half years later, she visited U hospital in Kochi Prefecture.
Tumor marker CA15-3 was 268. The increase in CA15-3 is inhibited by combined
treatment with chemotherapeutics and MGN-3. The patient's condition has been
rather good and she enjoys a typical lifestyle, continuing to visit the hospital
consistently.
When patient M.D. visited a hospital, a tumor was sticking out
the surface of the breast and resembled a cauliflower. When the patient entered
the hospital on August 2, 1997, the tumor marker was 14.6 for CA15-3 and 63.4 for
CEA. The patient took 3 g of MGN-3 per day. Though the marker was inhibited to
20.1 for CA15-3 and 65.1 for CEA on October 2nd, surgery was performed at the
patient's wish in January 1998. As of February 10, 1999, CEA had declined to 3.5
and the patient continues to take MGN-3 to prevent a recurrence, though she has
been in good condition.
Patient M.T. was found to have breast cancer in her right
breast on October 1, 1997. The tumor was hollowed with an ozone injection on
October 10th. In September 1998, the cancer transferred to the left breast and
the surface of the breast resembled a cauliflower and had begun bleeding. At this
point, the patient started taking 3 g MGN-3 per day. On January 18, 1999, the
patient had surgery, but metastasis to the lymph nodes was detected.
Fig. Changes in tumor marker levels
Evaluation
The effectiveness of MGN-3 was confirmed with these three cases
of breast cancer; one case was primary and the others were recurrent. In all
three cases, tumor markers did not increase during MGN-3 treatment, and MGN-3
apparently inhibited growth of the tumor. MGN-3's effective prolongation of life
is obvious because all of the patients are in good condition and
stable.
|
|
| No.20 Colonic Cancer/Liver Metastasis |
| NAME/B.I. |
AGE/67 |
SEX/Male |
RESIDENCE/Shizuoka Prefecture |
| Clinical Record and Treatment |
|
In January 1996, the patient had surgery for upper colonic
cancer. The possibility of metastasis was entertained due to misgivings about
the progression of colonic cancer. Though the patient was taking
chemotherapeutics, the tumor marker AFP started increasing in September and
liver metastasis was found in November. In April 1997, the patient's liver
cancer was excised. In February 1998, liver metastasis was found again and
excision was performed a second time. In November, a new metastasis was found
in the right lobe of the liver, but the physician in charge of this patient
indicated that further surgery would not be possible. In January 1999, the
patient started an injection of chemotherapeutics from the hepatic artery.
General prostration went on due to adverse effects associated with
chemotherapy. In February, the patient visited T clinic. After the patient
regulated intestinal conditions per the "partial fasting treatment" that was
employed as the base for cancer treatment at T clinic, he underwent original
dietetic therapy at this clinic and received 5 g MGN-3 per day. The rotation
of administration was five days of continuous treatment following two days
off.
Clinical Record and
Treatment
The tumor in the right lobe of the liver gradually shrunk,
and calcification rapidly progressed since around April 1999. The cancer had
been involuted and had calcified as a result of CT and echography. As of May,
the tumor marker CEA is normal at 1.2. The patient has rapidly recovered
physical strength since May and his entire body appears to be in good
condition.
Evaluation
The patient took MGN-3 when surgery did not seem possible
after three surgeries for liver metastasis due to colon cancer and
redetection of metastasis. The tumor was rapidly involuted by approximately 2
months of treatment. This is thought to be due to the immunopotentiation of
MGN-3. The patient is likely to continue MGN-3 intake to prevent
recurrence.
|
|
| No. 21 Stomach Cancer/T clinic |
| NAME/R.S |
AGE/62 |
SEX/Female |
RESIDENCE/Shizuoka Prefecture |
| Clinical Record and Treatment |
|
The patient felt something unusual when passing stool and
found blood mixed with the feces. The patient attended K city central
hospital in March 1997. On endoscopy, many polyps were found. According
to tissue diagnosis, the tumors were benign, class 3 and the larger ones
might become malignant; however, the patient did not receive any special
treatment and was examined again two years later by endoscopy in March
1999. On this occasion, the polyps were diagnosed as malignant tumors of
class 5 by tissue examination. Immediate surgery was recommended, but was
refused by the patient on considering her quality of life and she visited
T clinic on April 27. There she took 4g MGN-3 per day for
immunopotentiation in addition to "partial fasting treatment", and also
took 6 tablets of vegetable enzyme supplement per day to improve her
blood condition. On endoscopic examination 2 months later (July 12), all
polyps were diagnosed as benign, class 3. The sizes of polyps had
reduced. In January 1999, the patient experienced vomiting of blood and
was admitted to Y City Hospital. She was immediately hospitalized and a
malignant tumor was found in her stomach by endoscopy. The patient was
recommended complete excision of the tumor by surgery as the main
treatment due to the low possibility of metastasis, but she refused it.
On February 18, the patient again visited T clinic. Respecting the
patient's wishes, the clinic planned mainly dietetic treatment and
immunomodulatory treatment on the assumption that total gastrectomy would
be performed if no significant changes were observed. After the patient
regulated her intestinal conditions by "partial fasting treatment" that
was employed as basic treatment at T clinic, she underwent original
dietetic therapy at this clinic. MGN-3 was mainly used as an
immunopotentiating food. The dose and rotation of administration were 5g
per day, with five days of continuous treatment followed by two days off.
This administration was continued repeatedly for two months. Two weeks
after starting MGN-3, the pain had lessened and her appetite had
increased. One month later, the patient started gaining weight and, on
April 20, was 4 kg heavier than at the first consultation. The pain
almost disappeared. The patient had endoscopy in a professional hospital
at the end of May, and tumor tissue from 5 gastric sites were collected.
As a result of analysis of these samples, there was no malignancy.
Evaluation
This case was a fairly advanced stomach cancer and the
condition needed surgery for complete excision. However, surgery was
postponed at the patient's request and an alternative dietetic medical
treatment was conducted. The effect appeared significant, and the tumors
disappeared for a short period. No heterozygous cell was found in all
tissues from any area of stomach tumors. It is considered that the
immunopotentiating effect of MGN-3 was the motive power that led to a
successful result.
|
|
| No. 22 Prostate Cancer/T Clinic |
| NAME/T.O |
AGE/56 |
SEX/Male |
RESIDENCE/Shizuoka
Prefecture |
| Clinical Record and Treatment |
At the end of October 1998, the patient felt pain
around the abdomen with difficult micturition; he consulted M
Prefecture Medical Center. He was diagnosed with metastasis of the
lymph node due to prostate cancer on November 10. The level of PSA,
the prostate cancer marker, was 122. The patient immediately started
hormone therapy. At the end of January, 1999, when his PSA had
declined to 75, the patient left hospital. He continued regular
hormone therapy at hospital, but the PSA level remained at 77. The
patient felt limitations of hormone therapy and visited T clinic on
April 10, requesting treatment by alternative medicine. Hormone
therapy was conducted as the main treatment, adding dietetic therapy.
After the patient regulated his intestinal condition by "partial
fasting treatment" that was employed as the basic treatment at T
clinic, he underwent original dietetic therapy at this clinic. MGN-3
was mainly used as an immunopotentiating food. The dose and rotation
of administration were 5g per day, and five days of continuous
treatment following two days off. This administration was continued
for two months repeatedly. 
Changes due to
MGN-3
Three weeks after starting MGN-3, the abdominal
discomfort disappeared. The levels of PSA were 12 and 0.8 on May 14
and June 4, respectively. Nothing abnormal has been found in lymph
nodes.
Evaluation
Judging from the level of tumor marker, this was
metastasis in the lymph node from prostate cancer that might need
surgical treatment due to its active spread. It is considered that M
Prefecture Medical Center employed hormone therapy in order to
maintain function. The growth of tumor cells was suppressed by
hormone administration, which could not completely destroy the tumor.
The patient experienced a dramatic effect by adding alternative
medicine with dietetic treatment. MGN-3 worked as a motive power and
increased the effect of hormone therapy. A number of examples of
successful treatment of prostate cancer by MGN-3 have been reported,
and the present case would support those reports.
|
|
| No. 23 Metastatic Lung Cancer/T Clinic |
| NAME/K.I. |
AGE/55 |
SEX/Female |
RESIDENCE/Tokushima
prefecture |
| Clinical Record and Treatment |
|
In 1996, the patient felt pain and a swelling in
her right breast and consulted a doctor in Tokushima prefecture.
She was diagnosed with breast cancer and had surgery for complete
removal of the right breast. In January 1998, the patient felt
pain in the lymph nodes around the right armpit and consulted the
T clinic. The patient was diagnosed with metastatic cancer of the
lymph node and had surgery. In December 1998, a tumor 5 mm in
size was discovered by CT. The physician in charge recommended
chemotherapy, which the patient refused, feeling misgivings about
the decreased QOL caused by the side effects. The patient visited
T clinic in order to improve her physical constitution by
dietetic therapy on January 14, 1999. After her intestinal
condition was controlled by "partial fasting treatment" that was
employed as the basic treatment at T clinic, she underwent
original dietetic therapy at this clinic. The dose and rotation
of administration of MGN-3 were 4g per day, and five days of
continuous treatment following two days off. This administration
was continued for six months repeatedly.
Changes due to
MGN-3
Ten days after starting MGN-3, fatigue was
reduced and the patient felt herself recovering physical
strength. Lumbago and constipation were improved one month later
and the patient's physical condition was also improved
considerably. As a result of an examination at the beginning of
July, CT of lung was unchanged and the tumor marker CEA was below
0.7, which was within the normal range, and metastasis of the
lymph node was not found.
Evaluation
Although the lymph node was removed surgically,
it is considered that the chemotherapy was useful as long as
treatment of lung cancer continued. However, the chemotherapy was
not carreid out due to the patient's wish to give priority to her
quality of life, and instead she received alternative medicine
including dietetic therapy in T clinic. As a result, her health
condition was rapidly improved and no tumour growth was found.
The doctor responsible mentioned that all cancers might
disappear. It is considered that the food functions worked
sufficiently due to the intestinal conditions regulated by the
"partial fasting treatment". The patient's blood sugar level has
been stable after it decreased to 76mg/dl from
121mg/dl.
|
|
| No. 24 Pancreas Cancer, Gallbladder and Liver
Metastasis / T Clinic |
| NAME/N.S |
AGE/58 |
SEX/Male |
RESIDENCE/ |
| Clinical Record and Treatment |
|
The patient was anorexic since May 1999 and
felt heavy fatigue. As his body became yellow through
jaundice around the end of May, he consulted S hospital on
June 1st. The patient immediately received CT, MRI and
endoscopic examination and was diagnosed with gallbladder and
liver metastasis developing from pancreatic cancer. The
condition was relatively advanced and there seemed to be no
fundamental treatment other than palliative surgery in order
to lessen the jaundice. The patient was advised that his
remaining days would be one month or thereabouts. Therefore,
he left S hospital without treatment on June 14th. On the
next day, the patient visited T clinic, thinking "I shall do
anything if I die after all." The patient received the
"partial fasting treatment" completely, and took 5g MGN-3
daily for Immunomodulation and 8 tablets and 12 capsules of
two types of vegetable enzyme food for improvement of his
blood condition, respectively. The rotation was five days of
continuous treatment following two days off.
Changes due to
MGN-3
The patient's jaundice improved rapidly.
Fatigue, nausea and lumbago were also improved. The tumor
marker declined and liver function improved as
well.
Evaluation
This case was an advanced pancreatic cancer
that metastised extensively into the liver, and there was no
role for conventional cancer therapy except for palliative
treatments. The patient's immunity was enhanced by the
improvement in his intestinal condition and the inhibition of
nutrition to cancer tissues by the complete "partial fasting
treatment". The patient showed dramatic therapeutic effects
three weeks later and seemed to avoid the dangerous
situation. It is considered that the immunopotentiational
function of MGN-3 in particular worked as an enormous motive
power. However, in view of the initial situation, the
patient's situation is far from reassuring. Continuous
observation will be required on his future
progress.
|
|
| No. 25 Colon Cancer |
| NAME/N.S |
AGE/58 |
SEX/Male |
RESIDENCE/Okayama
prefecture |
| Clinical Record and
Treatment |
|
The patient experienced difficulty passing
stool, and observed fecal blood. He was diagnosed in K
city Central Hospital in March 1997. During endoscopy,
many polyps were discovered. These were diagnosed as
class 3 and benign, however, the larger ones had a
possibility to develop malignancy. The patient did not
receive any treatment and had an endoscopy two years
later, in March 1999. As a result of that examination,
the polyps were diagnosed as class 5 and malignant
tumors. The patient was recommended immediate surgery,
however, considering his QOL, he declined it and visited
T clinic on April 27, 1999. At T clinic, he received
dietetic treatment including "partial fasting treatment"
and 4g of MGN-3 for immune enhancement, and 6 tablets of
vegetable enzyme food for improvement of blood condition.
On endoscopy two months later on July 12th, all polyps
were diagnosed as class 3 and benign. The sizes of polyps
was reduced.
Evaluation
This is a case where a malignant tumor
was improved to benign by dietetic treatment and immune
enhancement. The patient did not lose the function of the
anus and maintained his QOL well. The immune enhancement
of MGN-3 appears to be significant and the continuous
intake is recommended.
|
|
| No. 26 Bladder
cancer Facility/T Hospital |
| Patient's name/Y.
I AGE/39
years SEX/Female |
|
History of past diseases and
treatments
The patient developed rheumatoid
arthritis while she was studying to be a dentist at a
dental department. She opened her dental clinic at
the age of 29 and had been engaged in a busy
practice. She had severe hematuria in February 1999
and was hospitalized for examination in the urology
department of a nearby hospital. Histopathological
study revealed bladder cancer. She was invited to
have an operation but refused considering QOL. She
chose to undergo treatment mainly consisting of
alternative medicine and tried various treatments. On
June 5, she visited this hospital for treatment. She
was immediately put on a restricted diet based on
semi-fasting. She was also recommended a daily dose
of 4-5 g of MGN-3 to enhance immunity and plant
enzymatic foods to improve blood profile. Pain upon
urination began to subside 2 weeks after the start of
treatment. In early July, 1 month after the start of
treatment, hematuria looked thinner suggesting a
rapid reduction in the size of the tumor. The value
of the tumor marker NMP-22 (normally 12 or less)
decreased from 58 on May 25 to 10 on July
28.
Evaluation of MGN-3
Bladder cancer decreased in size in
a short period by means of restricted diet and
immunopotentiation and disappeared as judged from
tumor marker test results. The young age and great
self-healing potential may have contributed to
dramatic improvement. However, since adherence to
conventional lifestyles is likely to cause recurrence
and new tumor growth, the patient needs careful
follow-up including health guidance.
|
|
| No. 27 Pulmonary
adenocarcinoma Facility/T Hospital |
| Patient's name/T.
T AGE/53
years SEX/Female AREA/Shizuoka
Prefecture |
|
History of past diseases and
treatments
The patient visited a nearby
hospital because she had been severely coughing
since October 1994 with sporadic bloody sputum.
In December 1994, she was diagnosed with
pulmonary adenocarcinoma and immediately
underwent surgery. The affected part was resected
but no anticancer drug was given nor was
radiotherapy administered because no metastatic
lesions were observed. No subsequent procedures
were performed excepting regular follow-up
examinations. The follow-up examination on
September 1998 revealed metastases in bilateral
lungs. These metastases were too extensive to
perform operation and radiotherapy so she was
recommended chemotherapy. She refused for fear of
losing physical strength due to adverse effects
and visited T Hospital on October 29, 1998,
seeking treatment that would enhance self-healing
potential. She was put on a special diet of T
Hospital mainly aimed at the improvement of
intestinal conditions and semi-fasting. The
patient was given functional foods such as MGN-3
4 g daily (a weekly cycle of 6 successive days of
taking and 1 day of pause was repeated), plant
enzymatic foods and processed brown rice
foods.
Changes caused by ingestion of
MGN-3
The values of the tumor maker
CEA (normally 2.8 or less) decreased from 12.7 as
of October 29, 1998, to 2.3 as of July 7. The
disease has improved such that most tumors are
indistinguishable in image findings and
macroscopic findings. The general condition of
the patient is subjectively and objectively
sufficient to enjoy life.
Evaluation of
MGN-3
This is a case in which
increased self-healing potential due to a
restricted diet led to involution of pulmonary
adenocarcinoma. Lack of treatment with
chemotherapeutics and radiation saved the
self-healing potential and helped
immunopotentiators such as MGN-3 to work
sufficiently.
|
|
| No. 28 Ovarian
tumor Facility/T Hospital |
| Patient's
name/N. S AGE/46
years SEX/Female |
|
History of past diseases and
treatments
The patient presented with
back pain at a nearby hospital in December
1998. The physician referred her to the
affiliated hospital of N Medical School where
she underwent ultrasonography. The result
revealed aggravation of endometriosis and
ovarian tumor forming an endopelvic tumor
mass that involved various tissues. The
patient was considered inoperable. The tumor
mass involved small and large intestines and
included impurities. The hospital performed
CT, MRI and other diagnostic tests until
April. Although malignancy was strongly
suspected, the patient received only hormone
therapy. The patient visited T Hospital on
April 12. She was put on a special diet of T
Hospital mainly aimed at the improvement of
intestinal conditions and semi-fasting while
measuring pulsation scores. The patient was
given functional foods such as MGN-3 5 g
daily (a weekly cycle of 5 successive days of
taking and 2 days of pause was repeated)
along with other crude drugs. The prognosis
was good but the patient complained of acute
abdominal pain on August 30 and was
immediately admitted to the affiliated
hospital of T University, where she was
operated on. The operation lasted several
hours and was successful. A 980 g tumor mass
measuring 9-cm ? 21-cm and 4 masses of
hysteromyoma were excised. The small and
large intestines, which had been examined in
April, were separated before the operation so
that the tumor and myoma could be easily
excised. Histopathological study showed that
these excised masses were all
benign.
Evaluation of
MGN-3
Examination in April showed
that the tumor mass involved small and large
intestines and was strongly suspected to be
malignant. Examination in August when the
operation was performed showed that the tumor
was benign though it appeared to be malignant
and it did not involve other organs. Whether
there was no involvement from the beginning
or treatment at T Hospital was effective is
not clear. However, dietary therapy and MGN-3
seem to have been effective in that an
inoperable patient was operated on with good
results, and with thanks from the patient and
her husband.
|
|
| No. 29 Pulmonary
adenocarcinoma Facility/T
Hospital |
| Patient's
name/M. U AGE/59
years SEX/Female AREA/Shizuoka
Prefecture |
|
History of past diseases
and treatments
On June 20, 1988, the
patient was admitted to S Central
Hospital for the treatment of dyspnea.
She had pleural effusion in bilateral
lungs and underwent surgery to draw a
large quantity of pleural effusion. She
was diagnosed with pulmonary
adenocarcinoma and remained at the
hospital for 4 months. She was readmitted
in 1989 for treatment and was given
anticancer drugs and antibiotics by
infusing them directly into the pulmonary
artery using catheters. She remained at
the hospital for about 3 years until
November 1992, when she was discharged
although she had not shown improvement.
She developed pneumonia in 1994 and 1995
and was told that she had only 3 months
to live. In May 1994, she joined the
religious organization "M Kyo." She
refused treatment at the hospital in May
1995 and discontinued hospital visits.
Because pleural effusion began to
reaccumulate, she resumed hospital visits
but received no special treatment apart
from taking natural foods. She developed
hematochezia at the end of 1995 but was
not treated. In December 1998,
hematochezia occurred at higher
frequencies and in larger quantities. She
visited this hospital on July 11, 1999.
She was treated with a special diet
featuring semi- fasting and MGN-3 4 g
daily plus enzymatic foods to enhance
immunopotency.
Changes caused by
ingestion of MGN-3
Hematochezia
disappeared and there were improvements
in fatigue-proneness, stiff neck,
backache and pain in the ridge. As of
November 29, 1999, radiography revealed
several round shadows in the lungs.
Although they are classified as
malignancies, the values for the tumor
marker were 1.4 for CEA and 36.4 for SLX
(normally 38 or less).
Evaluation of
MGN-3
This patient's course
of disease is unusual. Malignancy of the
disease was confirmed by
histopathological studies and
radiography. The patient seems to have
overcome the malignant disease through
her strong will. Dietary treatment and
immunopotentiation with MGN-3 may have
led to improvements in hematochezia and
pain and normalization of tumor marker
points. However, since malignancy is
still detected, careful follow-up
examination is necessary. Treatment at
this hospital must have enhanced the
resistance of the body, which enhanced
her spirit to play the main role in
fighting the disease.
|
|
|
